Drug Channels:New Survey Reveals the Operating Reality of Patient Access and Where Priorities Are Shifting

Patient services programs are modernizing, but progress is uneven. As specialty therapies grow more complex, many organizations are still working to align hub structures, technology, and data in ways that meaningfully support access.

In a recent guest post on Drug Channels, CareMetx Chief Product Officer Scott Genone shares insights from CareMetx’s 2026 Patient Services Report, which reflects perspectives from more than 100 patient access decision-makers across biopharma, consulting, and specialty care. One clear signal from the survey: while hybrid hub models have become the prevailing structure, the ability to effectively connect systems and activate data is increasingly determining how well those models perform.

Scott explores how technology adoption has reached a critical inflection point. Automation and point solutions are widely in place, but limitations in interoperability often prevent accurate data from being used in real time to drive workflows and decisions. Read the full article on Drug Channels. 

To see the full set of findings, including how leaders expect patient services priorities to evolve over the next 12 to 24 months, download the 2026 Patient Services Report.